logo-loader
RNS
viewReNeuron Group PLC

Clinical Update and Conference Presentations

/**/ h1{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .w{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.w{}p.bp{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}span.bn{font-size:12.0pt}table.bq{width:16.0cm;margin-left:-5.4pt;border-collapse:collapse}td.bk{width:176.65pt;padding:0cm 5.4pt 0cm 5.4pt}span.bl{font-family:"Calibri","sans-serif"}td.bi{width:255.35pt;padding:0cm 5.4pt 0cm 5.4pt}h3.bj{text-align: right}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;} h1.bg{text-align: center}p.br{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;text-align: center}span.bf{font-size:12.0pt;line-height:107%}p.bs{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;font-weight: bold; text-align: center}p.bt{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;font-div: italic; line-height: normal; margin-bottom: 0cm; text-align: center}p.bu{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;text-align:justify}span.ba{color:windowtext}table.bv{margin-left:-5.4pt;border-collapse:collapse;border:none}td.ay{width:74.0pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.az{font-size:11.0pt} td.ax{width:102.6pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.aw{width:116.8pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.av{width:74.0pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.au{width:102.6pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.at{width:116.8pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.ar{color:#1F497D}p.bw{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;font-weight: bold; text-align: justify}p.bx{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;text-align:justify;line-height:normal}p.by{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;font-weight: bold; text-align: center}table.bz{margin-left:-10.8pt;border-collapse:collapse;border:none} tr.al{height:28.75pt}td.an{width:299.4pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:28.75pt}p.ca{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;font-weight: bold}td.am{width:138.0pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:28.75pt}p.l,li.l,div.l{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;}tr.aj{height:6.0pt}td.ak{width:448.2pt;border:none; padding:0cm 5.4pt 0cm 5.4pt;height:6.0pt}td.ai{width:299.4pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:6.0pt}td.ah{width:138.0pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:6.0pt}tr.ae{height:20.6pt} td.ag{width:299.4pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:20.6pt}td.af{width:138.0pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:20.6pt}tr.ab{height:12.65pt}td.ad{width:299.4pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:12.65pt}td.ac{width:138.0pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:12.65pt}p.z{margin-top:0cm;margin-right:0cm;margin-bottom:15.0pt;margin-left: 0cm;text-align:justify;background:white}p.cb{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;font-div: italic; text-align: justify}span.x{font-size:11.0pt; color:windowtext} /**/
RNS Number : 4279O
ReNeuron Group plc
02 October 2019
 

 

2 October 2019

   AIM: RENE

 

ReNeuron Group plc

("ReNeuron" or the "Company")

Clinical update and conference presentations

"Clear efficacy signal" in Phase 2a study of hRPC cell therapy in retinitis pigmentosa

 

ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce new positive data in the Company's ongoing Phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).  

 

At most recent follow-up in the Phase 2a segment of the study, the mean improvements from baseline in visual acuity as measured by the number of letters read on the ETDRS chart (the standardised eye chart used to measure visual acuity in clinical trials) were as follows:

 

Months post-treatment

Mean improvement in visual acuity in treated eye

Mean improvement in visual acuity in treated eye (excluding two patients with procedure-related vision loss)

Mean change in visual acuity in untreated eye

1

+8.3 letters (n=8)

+14.5 letters (n=6)

+ 1.6 letters (n=8)

2

+5.4 letters (n=8)

+13.0 letters (n=6)

+ 2.8 letters (n=8)

3

+6.1 letters (n=8)

+17.8 letters (n=6)

+ 6.8 letters (n=8)

6

+18.5 letters (n=4)

+28.7 letters (n=3)

+ 7.8 letters (n=4)

9

+12.0 letters (n=1)

+12.0 letters (n=1)

 - 1.0 letter  (n=1)

 

The observed efficacy was rapid and profound in the first three patients in the Phase 2a segment of the study. Efficacy in subsequent patients has also been seen but at a lower rate and magnitude (improvement in visual acuity ranging from +5 to +11 letters in the treated eye 3 months post-treatment), with the ultimate extent of improvement not yet known as the study is ongoing. Overall, the improvements to date represent a clear signal of efficacy in a patient population where inexorable disease progression is the norm.

 

A total of 22 patients have now been treated in the Phase 1/2a study and a good safety profile has been established, with no patients experiencing product-related serious adverse events and two patients experiencing surgical procedure-related loss of vision.

 

These latest results will be presented in further detail by Pravin Dugel MD, Managing Partner, Retinal Consultants of Arizona, Phoenix, Arizona, and Clinical Professor, Roski Eye Institute, USC Keck School of Medicine, Los Angeles, California, at the American Academy of Ophthalmology Annual Meeting (AAO) in San Francisco, taking place on 12-15 October 2019.  Dr Dugel will present in a Late Breaking Developments session at the meeting on 12 October 2019.   

 

Olav Hellebø, Chief Executive Officer of ReNeuron, will give a presentation in the Gene and Cell Therapy Spotlight session during the Ophthalmology Innovation Summit ([email protected]) on 10 October 2019, preceding the AAO meeting.

 

Dr. Pravin Dugel commented:

 

"I am looking forward to presenting and discussing these encouraging data at the upcoming AAO meeting in San Francisco.  I believe that we are seeing a clear signal of efficacy in this patient population where any gain in vision, let alone the levels seen in some of these patients, is so hard to come by and so very much appreciated."

 

RP is a group of hereditary diseases of the eye that lead to progressive loss of sight due to cells in the retina becoming damaged and eventually dying.  The Company's RP clinical programme has been granted Orphan Drug Designation in both Europe and the US, as well as Fast Track designation from the FDA. 

 

The Phase 1/2a clinical trial is an open-label study to evaluate the safety, tolerability and preliminary efficacy of ReNeuron's hRPC stem cell therapy candidate in patients with advanced RP.  The Phase 2a segment of the study, which uses a cryopreserved hRPC formulation, enrols subjects with some remaining retinal function and is being conducted at two clinical sites in the U.S. -- Massachusetts Eye and Ear in Boston and Retinal Research Institute in Phoenix, Arizona.

 

ReNeuron's hRPC cell therapy candidate offers a number of potential advantages over alternative approaches to the treatment of RP.  Firstly, the cell therapy candidate is independent of the many specific genetic defects that collectively define RP as a disease, thereby allowing a much broader potential patient population to be eligible for the treatment.  Secondly, the cells are cryopreserved, enabling on-demand shipment and use at local surgeries and hospitals.  Finally, the cells are injected directly to the site of retinal degeneration, allowing a greater chance of anatomic restoration of photoreceptor function.   

 

The Company will continue to generate further longer-term follow up data from the ongoing Phase 1/2a study.  In parallel, the Company will consult with its advisers and regulatory authorities in Europe and the US in order to design and agree the future clinical development programme for its hRPC cell therapy candidate for the treatment of RP.

 

Olav Hellebø, Chief Executive Officer of ReNeuron, commented: 

"We are greatly encouraged by the latest efficacy data from the ongoing Phase 1/2a clinical study of our hRPC cell therapy candidate in patients with RP.   It is especially gratifying to see positive data given the inherent challenge in addressing a disease as complex as RP and we look forward to further progressing the clinical development of this promising cell therapy candidate."  

                                                                        ENDS

 

Contacts:

 

ReNeuron

 

 

+44 (0) 20 3819 8400

Olav Hellebø, Chief Executive Officer

Michael Hunt, Chief Financial Officer

 

Buchanan (UK Media/Investor Relations)

 

+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham

 

Argot Partners (US Media/Investor Relations)

Claudia Styslinger, David Rosen

 

+1 212 600 1902

 

 

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Jonathan Senior, Stewart Wallace, Ben Maddison

+44 (0) 20 7710 7600

 

 

N+1 Singer (Joint Broker)

Aubrey Powell, James Moat, Mia Gardner

 

+44 (0) 20 7496 3000

 

 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RESCKDDQKBDBKKK

Quick facts: ReNeuron Group PLC

Price: 134.4999

Market: LSE
Market Cap: £42.81 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18